Star Health Q1 FY27 Results Analysis: PAT Grows 25%, GWP Surges 19% (STARHEALTH)

CompoundingAI Research Updated July 29, 2026 2 min read
Neutral

Star Health & Allied Insurance Company Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 4,917.20 Cr (+13.39% YoY) and PAT growth of +25.46% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 29, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 4,917.20 Cr (+13.39% YoY)
PAT (Q1)Rs. 549.73 Cr (+25.46% YoY)
EPS (Q1)Rs. 9.34 (+25.37% YoY)
Market capRs. 35,226.11 Cr
CMPRs. 598.85

Quarter Snapshot

Star Health delivered a strong Q1FY27 with 18.91% GWP growth, combined ratio of 90.93%, and 25.46% PAT growth. The health segment is performing well, but the absence of explicit guidance and volatility in investment income limit forward visibility. Q2 typically sees higher claims due to monsoon season, so sustainability of margin improvement will be key.

Key Investment Insights

Key Positives

  • Gross Written Premium grew 18.91% YoY to Rs.4,287.13 Cr, accelerating from FY26 full-year growth of 11.31%.
  • Combined ratio improved 107 bps YoY to 90.93%, driven by claims ratio improvement of 104 bps to 67.48%.
  • Insurance Service Result surged 47.69% YoY to Rs.425.10 Cr, with margin expanding 201 bps to 8.65%.
  • PAT grew 25.46% YoY to Rs.549.73 Cr, while EPS rose 25.37% to Rs.9.34.
  • Health segment (98.8% of profit) delivered insurance revenue growth of 13.74% YoY and segment profit growth of 25.84% YoY.
  • Net worth grew 11.36% YoY to Rs.10,144.23 Cr, with negligible leverage (Debt/Equity 0.05x).

Risk Factors

  • Employee benefit expenses grew 21.93% YoY, above revenue growth, partly due to ESOP cost of Rs.12.49 Cr.
  • Personal Accident segment insurance revenue declined 11.55% YoY, though it turned from service loss to profit.
  • Travel segment insurance revenue declined 42.29% YoY and swung to a service loss of Rs.(4.44) Cr.
  • Investment income includes volatile FVTPL component (Rs.337.58 Cr this quarter vs Rs.(521.70) Cr in Q4FY26), which can swing materially.
  • No explicit management guidance for FY27 was provided in the filing, limiting forward visibility.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now